TremRx emerges from stealth mode
“Putting this research in historical context, it helps explain the uniquely powerful efficacy of the first successful vaccine developed for smallpox by Jenner in 1796,” Kupper said in a written statement. “Syringes had not yet been invented, so Jenner administered the first vaccine by disrupting the upper layers of skin with a specialized needle, a process similar to how the vaccinia virus was delivered in our study.”
According to the release, TremRx vaccines are not only easier to administer, but are created using safer engineered replication-deficient viruses. The company is pursuing the application of its novel vaccines to a wide range of diseases, including important infectious diseases and cancers with unmet medical needs.
TremRx President Eric Stromquist, former partner at a Boston investment firm, told Mass High Tech Friday that the company received seed money from angel investors, and will be looking for a Series A round from venture capital firms in the next year. The company currently has just a handful of employees, and is outsourcing several functions, he said.
In addition to Stromquist and Kupper, the company has two other team members: Mitch DeRosa, executive vice president and co-founder of skin care product company Living Proof, and Scientific Advisor Robert Langer, the David H. Koch Institute Professor at MIT and one of the largest patent holders in the world.
Langer, who is involved with scores of biotech companies around Cambridge, was awarded the 2011 Warren Alpert Foundation Prize  last fall.